Recent alignment among key research pillars supports a strategic move towards late preclinical and early clinical studies of epigenetic modulation techniques. These methods show promise in enhancing the efficacy of traditional cancer therapies through targeted gene expression control, while ongoing mechanistic mapping seeks to mitigate potential risks. With moderate development risks overshadowed by significant therapeutic upside, the path forward appears clear for integrating epigenetic strategies in clinical treatment regimens.